A longitudinal PET study on changes in brain norepinephrine transporter availability following duloxetine treatment in major depressive disorder.

ABSTRACT:

Importance

The norepinephrine transporter (NET) plays a crucial role in major depressive disorder (MDD). Serotonin and norepinephrine reuptake inhibitors, such as duloxetine, are first-line treatments for MDD. Duloxetine inhibits the reuptake of both serotonin and norepinephrine. However, its precise mechanism, particularly regarding NET occupancy and changes in transporter availability, remains unclear. Norepinephrine transmission, mediated by NET, may be instrumental in treating MDD. Therefore, NET occupancy could serve as a potential biomarker to evaluate treatment efficacy.

Objective

This study evaluated duloxetine's impact on brain NET availability in patients with MDD using positron emission tomography (PET) with (S,S)-[18F]FMeNER-D2 and its correlation with clinical s

SUBMITTER: Moriguchi S 

PROVIDER: S-EPMC12489337 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature